SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Indications -- Hepatitis
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Miljenko Zuanic who wrote (295)2/3/2018 1:51:04 PM
From: ghmm  Read Replies (1) of 312
 
GLPG... Its probably not going to happen because everyone thinks its inevitable :-)

The logic actually goes beyond their Filgotinib partnership (the standstill ended as of January I believe). Gilead's been active in Lung diseases and had a few IPF programs (GLPG1690 had some small but potentially quite promising results in IPF) and if the ABBV/GLPG partnership in CF should be terminated (To me it appears there are some disagreements between the two on development) that would make them much more attractive.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News